Dietary composition alters methotrexate toxicity without changing its pharmacokinetic parameters in cats

Journal of Nutritional Biochemistry

Volumn 8, Issue 2, 1997, Pages 79-84

  Marks, Stanley L ^a   Vulliet, P Richard ^a   Kass, Philip H ^a   Rogers, Quinton R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cat; enteritis; feline; methotrexate pharmacokinetics; purified diet

Indexed keywords

METHOTREXATE;

ANIMAL EXPERIMENT; ARTICLE; CAT; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN;

EID: 0031003558     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(96)00177-5     Document Type: Article

References (34)

1. Jolivet, J., Cowan, K.H., Curt, G.A., Clendeninn, N.J., and Chabner, B.A. (1983). The pharmacology and clinical use of methotrexate. N. Eng. J. Med. 309, 1094-1104
2. Djerassi, I. and Kim, J.S. (1976). Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas). Prolonged unmaintained remission. Cancer 38, 1043-1051
3. Matus, R.E. (1989). Chemotherapy of lymphoma and leukemia. In Current Veterinary Therapy X (R.W. Kirk, ed.), p. 482-488, W.B. Saunders Company, Philadelphia, PA USA
4. Allegra, C.J. (1990). Antifolates. In Cancer Chemotherapy: Principles and Practice (B.A. Chabner and J.M. Collins, eds.), p. 110-153, J.B. Lippincott Company, Philadelphia, PA USA
5. Bounous, G., Gentile, J.M., and Hugon, J. (1971). Elemental diet in the management of the intestinal lesion produced by 5-fluouracil in man. Can. J. Surg. 14, 312-314
6. Bounous, G., Gentile, J.M., and Hugon, J. (1971). Elemental diet in the management of the intestinal lesion produced by 5-fluouracil in the rat. Can. J. Surg. 14, 298-312
7. McAnena, O.J., Ridge, J.A., and Daly, J.M. (1987). Alteration of methotrexate metabolism in rats by administration of an elemental liquid diet. Reduced toxicity and improved survival using cholestyramine. Cancer 59, 1091-1097
8. McAnena, O.J., Harvey, L.P., Bonau, R.A., and Daly, J.M. (1987). Alteration of methotrexate toxicity in rats by manipulation of dietary components. Gastroent. 92, 354-360
9. McAnena, O.J., Rossi, M., Mehta, B.M., and Daly, J.M. (1987). Alteration of methotrexate metabolism in rats by administration of an elemental liquid diet. I. Changes in drug enterohepatic circulation. Cancer 59, 31-37
10. Kehoe, J.E., Harvey, L.P., and Daly, J.M. (1986). Alteration of chemotherapy toxicity using a chemically defined liquid diet in rats. Cancer Res. 46, 4047-4052
11. Funk, M.A. and Baker, D.H. (1991). Effect of fiber, protein source and time of feeding on methotrexate toxicity in rats. J. Nutr. 121, 1673-1683
12. Funk, M.A. and Baker, D.H. (1991). Effect of soy products on methotrexate toxicity in rats. J. Nutr. 121, 1684-1692
13. Shou, J., Lieberman, D., Hofmann, K., Leon, P., Redmond, H.P., Davies, H., and Daly, J.M. (1991). Dietary manipulation of methotrexate-induced enterocolitis. JPEN 15, 307-312
14. Copeland, E.M., MacFadyen, B.V., Lanzotti, V.J., and Dudrick, S.J. (1975). Intravenous hyperalimentation as an adjunct to cancer chemotherapy. Am. J. Surg. 129, 167-173
15. Torosian, M.H., Mullen, J.L., Miller, E.E., Zinnser, K.R., and Buzby, O.P. (1988). Reduction of methotrexate toxicity with improved nutritional status in tumor-bearing animals. Cancer 61, 1731-1735
16. Goldie, J.H., Price, L.A., and Harrap, K.R. (1972). Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern. Europ. J. Cancer. 8, 409-414
17. Schneiderman, M.A. (1967). Mouse to man: Statistical problems in bringing a drug to clinical trial. In Proc Fifth Berkeley Symp. Math. Statis. Prob. Univ of California 4, 855-866
18. Zaharko, D.S., Dedrick, R.L., and Bischoff, K.B. (1971). Methotrexate tissue distribution: prediction by a mathematical model. J. Natl. Cancer Inst. 46, 775-784
19. Perez, C., Wang, Y.M., Sutow, W.W., and Herson, J. (1978). Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin. Trials 1, 107-111
20. Greaves, J.P. (1965). Protein and calorie requirements of the feline. In Canine and Feline Nutritional Requirements (O. Graham-Jones, ed.) p. 33-45. Pergamon Press, London
21. Edelman, J., Biggs, D.F., Jamali, F., and Russell, A.S. (1984). Low-dose methotrexate kinetics in arthritis. Clin. Pharmacol. Ther. 35, 382-386
22. Huffman, D.H., Wan, S.H., Azarnoff, D.L., and Hoogstraten, B. (1973). Pharmacokinetics of methotrexate. Clin. Pharmacol. Ther. 14, 572-579
23. Stoller, R.G., Jacobs, S.A., Drake, J.C., Lutz, R.J., and Chabner, B.A. (1975). Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemother. Rep. 6, 19-24
24. Barber, A.E., Jones, W.G., Minei, J.P., Fahey, T.J., Moldawer, L.L., Rayburn, J.L., Fischer, E., Keogh, C.V., Shires, G.T., and Lowry, S.F. (1990). Glutamine or fiber supplementation of a defined formula diet: Impact on bacterial translocation, tissue composition, and response to endotoxin. JPEN. 14, 335-343
25. Chabner, B.A., Donehower, R.C., and Schilsky, R.L. (1981). Clinical pharmacology of methotrexate. Cancer Treat. Rep. 65, 51-54
26. Cotter, S.M. and Parker, L.M. (1978). High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Am. J. Vet. Res. 39, 1943-1945
27. Chabner, B.A., and Young, R.C, (1973). Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J. Clin. Invest. 52, 1804-1811
28. Sirotnak, F. and Moccio, D.M. (1980). Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse. Cancer Res. 40, 1230-1234
29. Pinedo, H.M., Zaharko, D.S., Bull, J., and Chabner, B.A. (1977). The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res. 37, 445-450
30. Pinedo, H.M., and Chabner, B.A. (1977). Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat. Rep. 61, 709-715
31. Evans, W.E., Crom, W.R., Abromowitch, M., Dodge, R., Look, A.T., Bowman, W.P., George, S.L., and Pui, C. (1986). Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N. Engl. J. Med. 314, 471-477
32. Evans, W.E., Stewart, C.F., Chen, C., Crom, W.R., Bowman, W.P., Abromowitch, M., and Simone, J.V. (1984). Methotrexate systemic clearance influences probability of relapse in children with standard risk acute lymphocytic leukemia. Lancet 1, 359-362
33. Borsi, J.D., Revesz, T., and Schuler, D. (1987). Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia. Cancer Chemother. Pharm. 19, 261-264
34. Chabner, B.A., Stoller, R.G., Hande, K.R., Jacobs, S., and Young, R.C. (1978). Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug Metab. Rev. 8, 107-117